Significant worldwide disparities in availability and timeliness of new cancer drugs
Despite considerable progress in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines worldwide, with poorer countries missing out, suggests a global analysis of new drug launches between 1990 and 2022, published in the open access journal BMJ Global Health.
Few new cancer drugs were launched in lower-middle or low income countries, and the gap between rich and poor nations widened over the three decades, the analysis shows.
Such inequities may help explain poor cancer outcomes in many countries, particularly those ...











